Highest Volume in Over a Year: These 2 Stocks Gain Up to 15%; Do You Own Them?
Join Us
Follow Us
In the first half of trading session, share price surged more than 15 per cent on the back of heavy volumes. As of 11:30 AM, total traded volume on the NSE had crossed the 3 crore mark, making it the highest-ever volume recorded in the stock’s history.
✨ AI Powered Summary
Indian equity markets extended their decline on Thursday, with the Sensex slipping below the 78,000 mark and the Nifty 50 falling under 24,200. The weakness was largely driven by a sharp rise in crude oil prices, which stayed above USD 100 per barrel, along with a broader sell-off across Asian markets.
Volume Buzzers of April 23, 2026
Even amid this volatile backdrop, stock-specific action remained strong, with a few counters witnessing a sharp rise in both price and trading volumes. Among the prominent volume buzzers were Small-Cap stock IRM Energy and pharmaceutical player Piramal Pharma.
IRM Energy Share Price in Focus as Volumes Surge
In the first half of Thursday’s trading session, IRM Energy share price surged more than 15 per cent on the back of heavy volumes. As of 11:30 AM, total traded volume on the NSE had crossed the 3 crore mark, making it the highest-ever volume recorded in the stock’s history.
IRM Energy is an integrated energy solutions provider focused on building a sustainable future through innovation and responsible operations. The company operates across the energy value chain, spanning development, generation, distribution, and energy-efficiency services, supported by technology, expertise, and strong stakeholder partnerships.
The stock has delivered strong momentum recently, rising 57 per cent over the past one month, while remaining marginally down by 2 per cent over the past one year.
Piramal Pharma Share Price up by Over 7%
Piramal Pharma share price also gained more than 7 per cent on Thursday, supported by robust trading activity. On the NSE, total traded volume crossed 3.10 crore shares as of 11:34 AM, marking the stock’s highest single-day volume since March 2025.
Piramal Pharma Limited offers a diversified portfolio of products and services through its 17 global development and manufacturing facilities, along with a distribution network spread across more than 100 countries. Its business includes Piramal Pharma Solutions, an integrated contract development and manufacturing organization; Piramal Critical Care, which focuses on complex hospital generics; and Piramal Consumer Healthcare, which sells over-the-counter consumer and wellness products.
In addition, one of its associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and Piramal Pharma, has emerged as a market leader in the ophthalmology therapy segment in India. The company also holds a strategic minority stake in Yapan Bio Private Limited, which operates in the biologics, biotherapeutics, and vaccine segments.
Piramal Pharma is scheduled to announce its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, on April 28.
Do you hold any of these volume buzzers in your portfolio? Let us know in the comments section.
Disclaimer: This article is for informational purposes only and not investment advice.